The natural antibiotic pristinamycin was isolated in 1955 from Streptomyces pristinaespiralis and belongs to the family Streptogramines (1) . This antibiotic is composed of several compounds which are slightly different and is classified into two groups, I and II (PIA and PIIA) (3) . This mixture, with defined percentages of compounds from both groups (Table 1) , achieves synergistic bacteriostatic and bactericidal activities which allows for a stronger combined activity compared with the individual activities of each component. This explains the name synergistin that was given to this group of compounds in general. Pristinamycin shares the antimicrobial activity spectrum of macrolides and lincosamides, but there are a smaller number of strains that are resistant to pristinamycin. It is a potent antistaphylococcal and antistreptococcal agent (except for some resistant enterococci), and for this reason, pristinamycin is especially useful in skin and bone infections. It is an especially welltolerated antibiotic, even when the treatment is continued for several months. It does not cause any significant toxic side effects in humans and is not known to be teratogenic. Owing to the multibacterial nature of skin infections in which aerobic and anaerobic bacteria can be isolated, it was of interest to investigate the activities of pristinamycin and its components against anaerobic bacteria that were isolated from suppurative lesions and to compare its activities with those of penicillin G, cefoxitin, chloramphenicol, metronidazole, and clindamycin, which are drugs that are commonly used in the treatment of anaerobic infections.
The 200 strains tested (Table 1) were collected from several French hospitals (1985 to 1986). Organisms were identified according to procedures recommended by Holdeman et al. (4) . Bacteroidesfragilis ATCC 25285 and Clostridium perfringens ATCC 13124 were obtained from the American Type Culture Collection (Rockville, Md.), and Propionibacterium acnes 85176 was obtained from the collection of the Institut Pasteur (Paris, France). These organisms were included with each run of susceptibility tests for quality control purposes.
The following antimicrobial agents were obtained from the indicated manufacturers: metronidazole, penicillin, pristinamycin, and its components, Specia; chloramphenicol, Roussel; cefoxitin, Merck Sharp & Dohme, West Point, Pa.; clindamycin, The Upjohn Co., Kalamazoo, Mich.
The organisms to be tested were inoculated into thiogly- The activity of pristinamycin against an important sample of anaerobic bacteria has never been studied previously. The sample chosen was representative of anaerobic bacteria that can be found in mixed aerobic-anaerobic cutaneous infections. Table 1 summarizes the susceptibility data of those species represented by more than five isolates in terms of the concentration of drug required to inhibit 50% and 90% of the strains, the range of MICs, and the percentages of strains inhibited at the break point. The susceptibilities of the remaining strains are summarized in Table 2 . Break points were based on standards established by the National Committee for Clinical Laboratory Standards (Villanova, Pa.), except those for pristinamycin and penicillin G, for which the criteria established by the Comite de l'Antibiogramme de la Socidtd Francaise de Microbiologie (2) were used.
At the break point, PIA and PIIA were active against the gram-positive, anaerobic bacteria except Peptococcus spp. PIA was active against Clostridium spp. and Peptostreptococcus spp.; and PIIA was active against Peptostreptococcus spp., Propionibacterium spp., and most of the other anaerobic, gram-positive nonsporulated bacilli. Joined together in the natural pristinamycin product, their actions reached the majority of gram-negative, anaerobic bacteria; all gram-positive strains (except one strain of Eubacterium limosum; MIC, 4 jig/ml) and 93% of anaerobic, gramnegative bacilli were inhibited. Neither PIA nor PIIA was In conclusion, there was seldom resistance of anaerobic bacteria derived from suppurative lesions to pristinamycin, and the activity of pristinamycin was noted to be similar to that of chloramphenicol. Its toxicity is known to be less than that of chloramphenicol, and considering its well-known antistaphylococcal and antistreptococcal actions, pristinamycin might be a valuable therapeutic agent for the treatment of mixed aerobic-anaerobic infections. Clinical evaluation of this drug is necessary to confirm these in vitro data.
